Company: OSRH
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-045947
Chunk: 285

Company: OSR Holdings, Inc.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 8
Chunk 285
---
 100.00%  Medical device distribution  Republic of Korea  Darnatein Co., Ltd. (“Darnatein”)   6,466,667,000    100.00%  Biotech (drug development)  Republic of Korea  OSR Holdings, Inc.   2,826,969    100.00%  SPAC  The United States 

Key financial information of the subsidiaries
at March 31, 2025 are as follows :

    Name of subsidiary 
    Asset  
    Liability  
    Equity  
    Sales  
    Net Income
(loss) 
  
    VAXIMM AG 
    $910,415  
    $386,254  
    $524,161  
    $-  
    $(78,609)
  
    RMC Co.,Ltd 
     2,040,181  
     1,568,695  
     471,486  
     761,272  
     (211,541)
  
    Darnatein Co.,Ltd 
     110,171  
     678,651  
     (568,481) 
     -  
     (141,742)
  
    OSR Holdings, Inc. 
     1,687,119  
     10,071,814  
     (8,384,695) 
     -  
     - 

5

Summaries
of entities, which are newly included in consolidation scope for the periods ended March 31, 2025 and 2024 are as follows:

  For the year ended March 31, 2025  Name of subsidiary  Reason  Type of purchase consideration  OSR Holdings, Inc.  Acquisition (*1)  Equity swap with shares of the Parent and OSR inc.’s share 

(*1)The
Parent acquired subsidiary in February 2025 and accounted for the acquisitions at March 31, 2025, which is deemed the acquisition date.

(2)Summary of significant accounting policies

a.Basis of presentation

The
accompanying unaudited condensed consolidated financial statements have been prepared pursuant to U.S. generally accepted accounting
principles (US-GAAP) and reflect all adjustments which are, in the opinion of management, necessary to a fair presentation of the results
of the interim periods presented, under the rules and regulations of the